Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia

Haematologica

Volumn 90, Issue 10, 2005, Pages 1380-1388

  Lee, Je Hwan ^a,b   Choi, Seong Jun ^a   Lee, Jung Hee ^a   Seol, Miee ^a   Lee, Young Shin ^a   Ryu, Seong Gil ^a   Park, Chan Jeoung ^a   Chi, Hyun Sook ^a   Lee, Moo Song ^a   Yun, SungCheol ^a   Lee, Jung Shin ^a   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Allogeneic HCT; AML; Anti leukemic effect; Extramedullary relapse; GVHD

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; COMPARATIVE STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA REMISSION; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; SALVAGE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE MARROW; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL;

EID: 27144445237     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 1994; 84:3603-12.
2. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-8.
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
4. Weiden PL, Sullivan KM, Floumoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-33.
5. Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998;95:10152-7.
6. Collins RH Jr, Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992;10:391-5.
7. Higano CS, Brixey M, Bryant EM, Durnam DM, Doney K, Sullivan KM, et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990; 50:175-7.
8. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet 1978;2:537-40.
9. Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ, et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the EBMT of 117 cases. Br J Haematol 1988;70:317-20.
10. Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78:838-43.
11. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995;13:1800-16.
12. Au WY, Kwong YL, Lie AK, Ma SK, Liang R. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 1999;17:45-52.
13. Chong G, Byrnes G, Szer J, Grigg A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000;26:1011-5.
14. Lee KH, Lee JH, Choi SJ, Kim S, Seol M, Lee YS, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003;32:835-42.
15. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997;19:709-19.
16. Michel G, Boulad F, Small TN, Black P, Heller G, Castro-Malaspina H, et al. Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis. Bone Marrow Transplant 1997;20:107-12.
17. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989;7:50-7.
18. Simpson DR, Nevill TJ, Shepherd JD, Fung HC, Horsman DE, Nantel SH, et al. High incidence of extramedullary relapse of AML after busulfan/ cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 1998; 22:259-64.
19. Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999;85:608-15.
20. Bekassy AN, Hermans J, Gorin NC, Gratwohl A. Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996;17:801-8.
21. Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;26:147-52.
22. Seo S, Kami M, Honda H, Kashima T, Matsumura T, Moriya A, et al. Extramedullary relapse in the so-called 'sanctuary' sites for chemotherapy after donor lymphocyte infusion. Bone Marrow Transplant 2000;25:226-7.
23. Choi SJ, Lee JH, Kim S, Seol M, Lee YS, Lee JS, et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a nigh incidence of isolated extramedullary relapse. Leukemia 2004; 18:1789-97.
24. Berthou C, Leglise MC, Herry A, Balcon D, Hardy E, Lessard M, Abgrall JF. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998;12:1676-81.
25. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997;89:3113-7.
26. Zomas A, Stefanoudaki K, Fisfis M, Papadaki T, Mehta J. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone Marrow Transplant 1998;21:1163-5.
27. Goldberg SL, Mangan KF, Klumpp TR, Cropper TM, Schnall SF, Macdonald JS. Lack of a graft-versus-leukemia effect in an immunologically privileged sanctuary site. Bone Marrow Transplant 1994;14:180-1.
28. Schafer H, Bader P, Kaiserling E, Klingebiel T, Handgretinger R, Kanz L, et al. Extramedullary relapses at uncommon sites after allogeneic stem cell transplantation. Bone Marrow Transplant 2000;26:1133-5.
29. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
30. Tutschka PJ, Beschorner WE, Hess AD, Santos GW. Cyclosporin-A to prevent graft-versus-host disease: a pilot study in 22 patients receiving allogeneic marrow transplants. Blood 1983;61:318-25.
31. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
32. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999;24:763-8.
33. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695-700.
34. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255-67.
35. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-20.
36. Cleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 1985;21:217-21.
37. St George K, Rinaldo CR Jr. Comparison of cytomegalovirus antigenemia and culture assays in patients on and off antiviral therapy. J Med Virol 1999;59: 91-7.
38. Pancholi P, Wu F, Della-Latta P. Rapid detection of cytomegalovirus infection in transplant patients. Expert Rev Mol Diagn 2004;4:231-42.
39. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
40. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35:1-39.
41. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54.
42. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-202.
43. Steyerberg EW, Eijkemans MJ, Van Houwelingen JC, Lee KL, Habbema JD. Prognostic models based on literature and individual patient data in logistic regression analysis. Stat Med 2000;19:141-60.
44. Seal HL. Studies in the history of probability and statistics: XXXV. Multiple decrements or competing risks. Biometrika 1977;64:429-39.
45. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54.
46. Dekker AW, van't Veer MB, Sizoo W, Haak HL, van der Lelie J, Ossenkoppele G, et al. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol 1997; 15: 476-82.
47. Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993;11:304-13.
48. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991;79:567-74.
49. Tavassoli M, Hardy CL. Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 1990;76:1059-70.
50. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992;90:1232-41.
51. Lanza F, Bi S, Castoldi G, Goldman JM. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 1993; 7:1570-5.
52. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6.
53. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992;10:561-91.
54. + cytotoxic T cells. Proc Natl Acad Sci USA 1994;91:4185-9.
55. Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism or tumor immune escape in leukemia patients. Blood 1999;94:3135-40.
56. Brouwer RE, Hoefnagel J, Borger van Der Burg B, Jedema I, Zwinderman KH, Starrenburg IC, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol 2001;115:298-308.
57. Singhal S, Powles R, Treleaven J, Horton C, Tait D, Meller S, et al. Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. Bone Marrow Transplant 1996;17:637-41.
58. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al. Busulfan bioavailability. Blood 1994;84:2144-50.
59. Kataoka I, Kami M, Takahashi S, Kodera Y, Miyawaki S, Hirabayashi N, et al. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Bone Marrow Transplant 2004;34:711-9.
60. Ishiyama K, Takami A, Shiobara S, Koizumi S, Nakao S. Graft-versus-leukemia effect of allogeneic stem cell transplantation; a Japanese single center study. Haematologica 2004;89:887-9.